Brief: Curevac Announces Phase 2 Interim Data From Seasonal Influenza Vaccine Development Program In Collaboration With GSK
04/04/2024 12:31
April 4 (Reuters) - CureVac NV 5CV.DE :
* CUREVAC NV - CUREVAC ANNOUNCES PROMISING PHASE 2 INTERIM
DATA
FROM SEASONAL INFLUENZA VACCINE DEVELOPMENT PROGRAM IN
COLLABORATION WITH GSK
* CUREVAC NV - CANDIDATE SHOWED ACCEPTABLE SAFETY PROFILE
Further company coverage: 5CV.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CureVac NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Biontech Closes Acquisition Of CureVac
Brief: BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025
Brief: Curevac Reaffirms Its Expected Cash Runway Into 2028